MiMedx Group (NASDAQ:MDXG) Stock Rating Upgraded by Wall Street Zen

MiMedx Group (NASDAQ:MDXG) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts also recently commented on MDXG. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MiMedx Group in a research note on Thursday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Craig Hallum increased their price target on MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday. Seaport Research Partners lowered MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Finally, Raymond James Financial set a $8.00 price objective on MiMedx Group in a report on Monday, August 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.57.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $4.50 on Friday. The company has a 50 day moving average price of $4.18 and a two-hundred day moving average price of $4.09. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. The company has a market capitalization of $655.92 million, a PE ratio of 112.53 and a beta of 1.45. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.97.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million for the quarter, compared to analysts’ expectations of $63.46 million. Analysts forecast that MiMedx Group will post -0.1 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors have recently added to or reduced their stakes in the stock. SkyView Investment Advisors LLC boosted its holdings in shares of MiMedx Group by 3.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares during the period. Rafferty Asset Management LLC raised its holdings in MiMedx Group by 4.6% in the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after acquiring an additional 3,064 shares during the period. Aviva PLC lifted its position in MiMedx Group by 4.7% during the fourth quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after acquiring an additional 3,211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in MiMedx Group by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in shares of MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after acquiring an additional 4,296 shares during the period. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.